NEW YORK (GenomeWeb) – 23andMe today announced it has raised $115 million in a Series E financing round that will go toward expanding the company's operations and "maximize the potential of its direct-to-consumer product in the US and abroad." 

Fidelity Management & Research led the financing and was joined by new investors Casdin Capital, WuXi Healthcare Ventures, and Xfund. Existing investors Illumina, New Enterprise Associates, MPM Capital, and Google Ventures also participated in the round. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.